{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-023015","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.813061+00:00","generated_at":"2026-05-24T23:03:54.969006+00:00","sec_items":["1.01","2.03","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026","bullets":["$10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.","Loan matures March 12, 2026; proceeds to fund development of phage candidates AP-PA02 and AP-SA02.","Amendments extend maturity of three prior Innoviva credit agreements also to March 12, 2026.","Innoviva is Armata's largest shareholder; loan guaranteed by domestic subsidiaries.","Company pursuing additional non-dilutive funding for late-stage trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-023015","json":"https://secwatch.observer/filing/0001104659-25-023015.json","markdown":"https://secwatch.observer/filing/0001104659-25-023015.md","text":"https://secwatch.observer/filing/0001104659-25-023015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/0001104659-25-023015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:03:54.969006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e382a7658010f4030c9dd6eb4a23e4c515ffda51","claim":"Armata Pharmaceuticals, Inc. incurred credit facility of $10 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing March 12, 2026.","evidence_excerpt":"The March 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $10 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of March 12, 2026.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/0001104659-25-023015-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$10 million"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Rate","value":"14.0% per annum"},{"label":"Maturity","value":"March 12, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}